Study #2020-0305
A Phase 1, Open-Label, Multi-Center, Dose-Finding, Pharmacokinetic, Safety and Tolerability Study of PF-07265807 in Participants with Selected Advanced or Metastatic Solid Tumor Malignancies
MD Anderson Study Status
Not Accepting
Treatment Agent
PF-07265807, Sasanlimab, Axitinib
Description
A First-in-Human Pharmacokinetic, Safety, and Tolerability Study of PF-07265807 as Monotherapy and in Combination in Participants with Advanced or Metastatic Solid Tumors
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Neoplasm Metastasis
Study phase:
Phase I
Physician name:
David Sanghyun Hong
Department:
Investigational Cancer Therapeutics
For general questions about clinical trials:
1-866-720-1940
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.